Resistin in idiopathic inflammatory myopathies

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Filková, Mária ^a   Hulejová, Hana ^a   Kuncová, Klára ^a   Pleštilová, Lenka ^a   Cerezo, Lucie A ^a   Mann, Heřman ^a   Klein, Martin ^a   Zámečník, Josef ^a   Gay, Steffen ^b   Vencovský, Jiří ^a   Šenolt, Ladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGLOBIN; RESISTIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MONONUCLEAR CELL; MUSCLE CELL; MUSCLE INJURY; MUSCLE STRENGTH; MUSCLE TISSUE; MYOSITIS; PATHOGENESIS; PROTEIN EXPRESSION; BLOOD; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOSITIS; REAL-TIME POLYMERASE CHAIN REACTION; RESISTIN;

EID: 84860818276     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3836     Document Type: Article

References (34)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982. 10.1016/S0140-6736(03)14368-1, 14511932.
2. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009, 21:610-616. 10.1097/BOR.0b013e3283317b31, 19726994.
3. Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009, 133:157-170. 10.1016/j.clim.2009.07.013, 19740705.
4. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
5. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007, 92:2272-2279. 10.1210/jc.2006-2545, 17374708.
6. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1:e45. 10.1371/journal.pmed.0010045, 529430, 15578112.
7. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286-290. 10.1016/j.bbrc.2003.07.003, 12951047.
8. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS ONE 2006, 1:e31. 10.1371/journal.pone.0000031, 1762367, 17183659.
9. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70:146-157. 10.1016/j.cardiores.2006.01.015, 16515776.
10. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740. 10.1161/01.CIR.0000084503.91330.49, 12874180.
11. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314:415-419. 10.1016/j.bbrc.2003.12.104, 14733921.
12. Tomasová Studynková J, Charvát F, Jarosová K, Vencovsky J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2007, 46:1174-1179.
13. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
14. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003, 61:288-289. 10.1212/WNL.61.3.288, 12913184.
15. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
16. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, . International Myositis and Clinical Studies Group (IMACS) International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic infl ammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology(Oxford) 2004, 43:49-54. International Myositis and Clinical Studies Group (IMACS).
17. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010, 62:465-472.
18. Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J, Müller-Ladner U, Gay S. Adipocytokines in synovial fluid. JAMA 2003, 290:1709-1710. 10.1001/jama.290.13.1709-c, 14519704.
19. Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, Anderlová K, Müller-Ladner U, Pavelka K, Haluzík M. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007, 66:458-463. 1856051, 17040961.
20. Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H, Eguchi K. The serum evels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006, 24:698-701.
21. Almehed K, d'Elia HF, Bokarewa M, Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R15. 10.1186/ar2366, 2374439, 18234104.
22. Baker JF, Morales M, Qatanani M, Cucchiara A, Nackos E, Lazar MA, Teff K, Von Feldt JM. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 2011, 38:2369-2375. 10.3899/jrheum.110237, 21885493.
23. Karalaki M, Fili S, Philippou A, Koutsilieris M. Muscle regeneration: cellular and molecular events. In Vivo 2009, 23:779-796.
24. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1173-1187. 10.1152/ajpregu.00735.2009, 2867520, 20219869.
25. Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?. J Intern Med 2011, 269:243-257. 10.1111/j.1365-2796.2010.02334.x, 21205023.
26. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
27. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 1999, 97:642-648. 10.1007/s004010051041, 10378384.
28. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticoid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000, 43:336-348. 10.1002/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V, 10693873.
29. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436-3446. 10.1002/art.24936, 19877033.
30. Mackiewicz Z, Hukkanen M, Povilenaite D, Sukura A, Fonseca JE, Virtanen I, Konttinen YT. Dual effects of caspase-1, interleukin-1 beta, tumour necrosis factor-alpha and nerve growth factor receptor in inflammatory myopathies. Clin Exp Rheumatol 2003, 21:41-48.
31. Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, Kim DS, Baek SH, Lee SH, Lee JH, Kim HY, Kim SI. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2010, 29:273-279. 10.1007/s10067-009-1316-7, 2812423, 19953283.
32. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010, 14:1419-1431.
33. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 2010, 12:198-203. 10.1007/s11926-010-0101-6, 2929916, 20425524.
34. Tournadre A, Lenief V, Eljaafari A, Miossec P. Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2012, 64:533-541.